CJC-1295 vs Epithalon
Side-by-Side Comparison
| Attribute | Cjc 1295 | Epithalon |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Telomere |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only / No approved human indication in Western countries |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Generally well tolerated; no serious adverse events reported in decades of Russian clinical use; Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 5–10 mg/day SC |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~390.3 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Several hours |
Overview
CJC-1295 and Epithalon are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Epithalon — Mechanism & Evidence
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Key claims: Activates telomerase and extends telomeres; Extends lifespan in animal models; Restores melatonin production and sleep quality.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
Epithalon is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Epithalon: Generally well tolerated; no serious adverse events reported in decades of Russian clinical use Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported Mild headaches, dizziness, and GI discomfort possible
Related Products
Related Research News
Epithalon Research: Telomerase Activation and Longevity Effects
Epithalon, a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG), activates telomerase in human cells, leading to telomere elongation according to studies by Vladimir Khavinson's group. Research also shows lifespan extensions of 6% to 25% in rodents, reduced tumor incidence, and restored melatonin rhythms in aging models. These findings link the peptide to pineal gland function and oxidative stress reduction, though independent replication remains limited.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.